Hyperlipidemias Completed Phase 3 Trials for Bococizumab (DB12456)

Also known as: Hyperlipidemia / Hyperlipemia / Hyperlipidaemia / Hyperlipaemia / Hyperlipidemia, unspecified / Lipidemia / Hyperlipidaemia NOS

IndicationStatusPhase
DBCOND0031916 (Hyperlipidemias)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01968967Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular EventsTreatment
NCT02100514Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular EventsTreatment
NCT02135029Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to StatinsTreatment
NCT02458287Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or DyslipidemiaTreatment
NCT01968954Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular EventsTreatment